<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524017</url>
  </required_header>
  <id_info>
    <org_study_id>J0644 CDR0000562250</org_study_id>
    <secondary_id>P50CA096784</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0644</secondary_id>
    <secondary_id>JHOC-NA_00001757</secondary_id>
    <nct_id>NCT00524017</nct_id>
  </id_info>
  <brief_title>Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract</brief_title>
  <official_title>Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as cetuximab, can block abnormal cell growth in
      different ways. Some block the ability of abnormal cells to grow and spread. Others find
      abnormal cells and help kill them or carry cell-killing substances to them.

      PURPOSE: This randomized phase II trial is studying how well cetuximab works in treating
      patients with precancerous lesions of the upper aerodigestive tract.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the histologic response rate in patients with high-risk, premalignant
           lesions of the upper aerodigestive tract treated with cetuximab.

      Secondary

        -  To determine the clinical response rate in these patients.

        -  To determine if patterns of epidermal growth factor receptor (EGFR) component expression
           are altered in these patients.

        -  To determine the change in status of genetic alterations, including loss of
           heterozygosity, in these patients.

      OUTLINE: This is a multicenter study. Patients are stratified by lesion type [diffuse
      dysplasia vs recurrent dysplasia vs dysplastic lesions with 3p or 9p loss of heterozygosity
      (LOH)]. Patients are randomized to 1 of 2 arms.

        -  Arm I (treatment): Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22,
           29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.

        -  Arm II (control): Patients receive regular follow-up care. Patients have the option of
           receiving cetuximab after completion of the study.

      In both arms, patients with persistent or recurrent high-grade dysplasia or dysplastic
      lesions with 3p or 9p LOH undergo surgical resection, if feasible, after week 8.

      Tumor biopsy samples are obtained at baseline* and after week 8 for histologic and biomarker
      correlative studies. Tissue samples are analyzed by histopathology to determine histologic
      changes in post-treatment lesions and by immuno-histochemistry (IHC) to measure expression
      and activation of EGFR signaling pathway components. LOH studies are also performed.

      NOTE: *Paraffin-embedded tissue from the original diagnostic biopsy may be used for baseline
      assessment, if the diagnostic biopsy was performed within 3 months prior to study entry.

      After completion of study therapy, patients are followed at approximately 1 month, every 3
      months for 2 years, and then every 6 months for up to 5 years as per routine standard of
      care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Objective Response Based on Histologic Grade</measure>
    <time_frame>8 weeks</time_frame>
    <description>Histologic downgrade by at least one grade of dysplasia (e.g Severe to Moderate).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Objective Response Based on Clinical Assessment</measure>
    <time_frame>8 weeks</time_frame>
    <description>Clinical visualization on whether lesion responded to treatment (i.e., direct visualization of the lesion combined with histologic grade)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of Epidermal Growth Factor Receptor (EGFR) Pathway Components and Molecular Alterations in Pre-treatment Biopsies</measure>
    <time_frame>Baseline (pre-treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of EGFR Pathway Components and Molecular Alterations in Post-treatment Biopsies</measure>
    <time_frame>At 8 weeks post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Up to year 5 years post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Recurrence</measure>
    <time_frame>Up to year 5 years post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Arm I (treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (control)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receive regular follow-up care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>given IV</description>
    <arm_group_label>Arm I (treatment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed high-risk, premalignant lesions of the upper aerodigestive
             tract, meeting one of the following criteria:

               -  Unresectable, diffuse high-grade dysplasia, defined as moderate or severe
                  dysplasia that is not assessable by physical examination and/or that cannot be
                  excised by standard surgical techniques

               -  previously treated HNSCC with persistent or recurrent high grade dysplasia with
                  no evidence of head and neck malignancy for three months prior to enrollment or
                  who have successfully completed therapy for head and neck malignancy more than 3
                  months prior to enrollment.

               -  Dysplastic lesions with 3p or 9p loss of heterozygosity

          -  Disease location amenable to endoscopic biopsy in an outpatient clinical setting or
             operative biopsy within the routine scheduling and practice of clinical care

               -  No medical contraindication to biopsy of the target lesion

               -  Pathology must be reviewed by the Johns Hopkins Hospital Department of Pathology

        PATIENT CHARACTERISTICS:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Absolute neutrophil count (ANC) &gt; 1,000/mm³

          -  Platelet count &gt; 75,000/mm³

          -  Creatinine clearance &gt; 60 mL/min

          -  Total serum bilirubin &lt; 1.5 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study therapy

          -  No concurrent illness likely to preclude study therapy or surgical resection

          -  Patients with a history of a curatively treated malignancy are eligible provided they
             are disease-free and have a survival prognosis that exceeds 5 years

          -  No evidence of clinically active interstitial lung disease

               -  Patients with chronic, stable radiographic changes who are asymptomatic are
                  eligible

          -  No history or radiological evidence of pulmonary fibrosis

          -  No acute myocardial infarction within the past 3 months

          -  No uncontrolled angina, arrhythmia, or congestive heart failure

          -  No evidence of other severe or uncontrolled systemic disease (e.g., unstable or
             uncompensated respiratory, cardiac, hepatic, or renal disease)

          -  No evidence of any other significant clinical disorder or laboratory finding that
             would preclude study participation

          -  No known severe hypersensitivity to cetuximab or any of its excipients

          -  No prior hypersensitivity reaction to chimerized or murine monoclonal antibody therapy

          -  No severe abnormality of the cornea

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from prior oncologic or other major surgery or biopsy

          -  More than 30 days since prior non-approved or investigational drugs

          -  No prior chemotherapy, radiotherapy, or surgery for the premalignant lesions

          -  No prior EGFR-targeted agents (e.g., cetuximab, gefitinib, or erlotinib)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Califano, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucille P. Markey Cancer Center at University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenebaum Cancer Center at University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Institute at New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2007</study_first_posted>
  <results_first_submitted>February 13, 2020</results_first_submitted>
  <results_first_submitted_qc>February 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 12, 2020</results_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypopharyngeal cancer</keyword>
  <keyword>laryngeal cancer</keyword>
  <keyword>lip and oral cavity cancer</keyword>
  <keyword>nasopharyngeal cancer</keyword>
  <keyword>oropharyngeal cancer</keyword>
  <keyword>paranasal sinus and nasal cavity cancer</keyword>
  <keyword>salivary gland cancer</keyword>
  <keyword>precancerous condition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study enrolled patients with premalignant lesions of the Head and Neck with mild, moderate or severe dysplasias</recruitment_details>
      <pre_assignment_details>16 participants did not have biopsy proven dysplasia as required by protocol and were not randomized to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Treatment)</title>
          <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.
cetuximab: given IV</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Control)</title>
          <description>Patients receive regular follow-up care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Treatment)</title>
          <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.
cetuximab: given IV</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Control)</title>
          <description>Patients receive regular follow-up care</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Objective Response Based on Histologic Grade</title>
        <description>Histologic downgrade by at least one grade of dysplasia (e.g Severe to Moderate).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Treatment)</title>
            <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.
cetuximab: given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Control)</title>
            <description>Patients receive regular follow-up care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Objective Response Based on Histologic Grade</title>
          <description>Histologic downgrade by at least one grade of dysplasia (e.g Severe to Moderate).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Objective Response Based on Clinical Assessment</title>
        <description>Clinical visualization on whether lesion responded to treatment (i.e., direct visualization of the lesion combined with histologic grade)</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Treatment)</title>
            <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.
cetuximab: given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Control)</title>
            <description>Patients receive regular follow-up care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Objective Response Based on Clinical Assessment</title>
          <description>Clinical visualization on whether lesion responded to treatment (i.e., direct visualization of the lesion combined with histologic grade)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Status of Epidermal Growth Factor Receptor (EGFR) Pathway Components and Molecular Alterations in Pre-treatment Biopsies</title>
        <time_frame>Baseline (pre-treatment)</time_frame>
        <population>Data was not collected for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Treatment)</title>
            <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.
cetuximab: given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Control)</title>
            <description>Patients receive regular follow-up care</description>
          </group>
        </group_list>
        <measure>
          <title>Status of Epidermal Growth Factor Receptor (EGFR) Pathway Components and Molecular Alterations in Pre-treatment Biopsies</title>
          <population>Data was not collected for this outcome</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Status of EGFR Pathway Components and Molecular Alterations in Post-treatment Biopsies</title>
        <time_frame>At 8 weeks post-treatment</time_frame>
        <population>Data was not collected for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Treatment)</title>
            <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.
cetuximab: given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Control)</title>
            <description>Patients receive regular follow-up care</description>
          </group>
        </group_list>
        <measure>
          <title>Status of EGFR Pathway Components and Molecular Alterations in Post-treatment Biopsies</title>
          <population>Data was not collected for this outcome</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <time_frame>Up to year 5 years post-treatment</time_frame>
        <population>No patients were followed for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Treatment)</title>
            <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.
cetuximab: given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Control)</title>
            <description>Patients receive regular follow-up care</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <population>No patients were followed for this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Recurrence</title>
        <time_frame>Up to year 5 years post-treatment</time_frame>
        <population>No patients were followed for this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Treatment)</title>
            <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.
cetuximab: given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Control)</title>
            <description>Patients receive regular follow-up care</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Recurrence</title>
          <population>No patients were followed for this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Treatment)</title>
          <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.
cetuximab: given IV</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Control)</title>
          <description>Patients receive regular follow-up care</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Zubair Khan</name_or_title>
      <organization>SKCCC</organization>
      <phone>4109553157</phone>
      <email>zkhan@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

